Williams Jones Wealth Management’s REGENERX BIOPHARMACEUTICALS RGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-10,000
| Closed | -$170 | – | 567 |
|
|
2023
Q3 | $170 | Hold |
10,000
| – | – | ﹤0.01% | 550 |
|
|
2023
Q2 | $266 | Hold |
10,000
| – | – | ﹤0.01% | 532 |
|
|
2023
Q1 | $1.05K | Hold |
10,000
| – | – | ﹤0.01% | 570 |
|
|
2022
Q4 | $1.39K | Hold |
10,000
| – | – | ﹤0.01% | 562 |
|
|
2022
Q3 | $1K | Hold |
10,000
| – | – | ﹤0.01% | 575 |
|
|
2022
Q2 | $2K | Hold |
10,000
| – | – | ﹤0.01% | 577 |
|
|
2022
Q1 | $2K | Sell |
10,000
-200,000
| -95% | -$40K | ﹤0.01% | 531 |
|
|
2021
Q4 | $34K | Hold |
210,000
| – | – | ﹤0.01% | 487 |
|
|
2021
Q3 | $35K | Hold |
210,000
| – | – | ﹤0.01% | 481 |
|
|
2021
Q2 | $57K | Hold |
210,000
| – | – | ﹤0.01% | 484 |
|
|
2021
Q1 | $53K | Hold |
210,000
| – | – | ﹤0.01% | 482 |
|
|
2020
Q4 | $93K | Buy |
210,000
+10,000
| +5% | +$4.43K | ﹤0.01% | 454 |
|
|
2020
Q3 | $80K | Hold |
200,000
| – | – | ﹤0.01% | 418 |
|
|
2020
Q2 | $63K | Hold |
200,000
| – | – | ﹤0.01% | 403 |
|
|
2020
Q1 | $38K | Hold |
200,000
| – | – | ﹤0.01% | 372 |
|
|
2019
Q4 | $28K | Buy |
200,000
+60,000
| +43% | +$8.4K | ﹤0.01% | 437 |
|
|
2019
Q3 | $22K | Buy |
+140,000
| New | +$22K | ﹤0.01% | 422 |
|
Williams Jones Wealth Management's RGN Position: Q4 2023 in Review
Williams Jones Wealth Management sold out of REGENERX BIOPHARMACEUTICALS (RGN) in Q4 2023, closing a stake of 10,000 shares — an estimated $170 sold.
Williams Jones Wealth Management first reported a position in RGN in Q3 2019 and held it in 17 quarters. The position peaked at $93K in Q4 2020. 0 funds tracked by Wall St. Rank hold RGN as of Q4 2023.
- Williams Jones Wealth Management reported no remaining REGENERX BIOPHARMACEUTICALS position as of Q4 2023 after selling out during the quarter.
- Williams Jones Wealth Management sold 10,000 REGENERX BIOPHARMACEUTICALS shares in Q4 2023, an estimated $170.
- Williams Jones Wealth Management first reported a position in REGENERX BIOPHARMACEUTICALS in Q3 2019 and held it in 17 quarters.
- Williams Jones Wealth Management's REGENERX BIOPHARMACEUTICALS position peaked at $93K in Q4 2020.
- 0 funds tracked by Wall St. Rank held REGENERX BIOPHARMACEUTICALS as of Q4 2023.
Based on Williams Jones Wealth Management's 13F filing for Q4 2023, filed 14 Feb 2024.